MNTS Stock: $76M Cash, No Debt, and the Ownership Test
Momentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
7Results4Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
DVLT $2B structured financing explained for beginners
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDVLT institutional flow check: financing signal, not a supply-crunch thesis
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenDVLT $2B HELMEX Mystery: Is the Address Really the Red Flag?
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDVLT 8-K: $2B headline, $25M cash test
Datavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenAEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runway
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAchieve Life Sciences: the quit-smoking pill with $180 million and an FDA manufacturing detour
Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
Open